Literature DB >> 22236667

Radiobiological principles: their application to γ knife therapy.

John W Hopewell1, William T Millar, Christer Lindquist.   

Abstract

Gamma Knife treatments are regarded as single dose exposures, however, in reality the total dose delivered is the addition of a variable number of individual smaller doses from the variable number of iso-centres or shots, selected to cover a lesion. The dose prescription, in terms of dose and dose rate, to different points on a given physical iso-surface, will vary according to location. In radiobiological terms this treatment pattern does not represent a single exposure, but a schedule with a variable number of different sized dose fractions given at different dose rates with multiple incompletes repair intervals (the time between shots). Using the concept of biologically effective dose (BED), incorporating a fast and a slow component of repair, the biological effectiveness of a 12-shot protocol was found to vary with the decay in the activity of the (60)Co sources and the time interval between shots. However, the largest effect was found when this standard protocol was compared with one involving only 2 shots. It should be recognised in individual Gamma Knife treatments that there are many variables which have the potential to influence the biological effective of the treatment and thus the importance of a single variable may be difficult to determine in isolation. Reports in the literature support the results of these simulated calculations into the factors likely to change the biologically effective dose with the use of the Gamma Knife.
Copyright © 2012 S. Karger AG, Basel.

Mesh:

Year:  2012        PMID: 22236667     DOI: 10.1159/000331173

Source DB:  PubMed          Journal:  Prog Neurol Surg        ISSN: 0079-6492


  8 in total

1.  Impact of the skull contour definition on Leksell Gamma Knife® Icon™ radiosurgery treatment planning.

Authors:  Henri-Arthur Leroy; Constantin Tuleasca; Michele Zeverino; Elodie Drumez; Nicolas Reyns; Marc Levivier
Journal:  Acta Neurochir (Wien)       Date:  2020-06-18       Impact factor: 2.216

2.  Impact of Decaying Dose-rate in Gamma Knife Radiosurgery.

Authors:  John W Hopewell; William T Millar; Ian Paddick; Christer Lindquist
Journal:  J Radiosurg SBRT       Date:  2013

3.  Application of the concept of biologically effective dose (BED) to patients with Vestibular Schwannomas treated by radiosurgery.

Authors:  John W Hopewell; William T Millar; Christer Lindquist; Håkan Nordström; Pär Lidberg; Jonas Gårding
Journal:  J Radiosurg SBRT       Date:  2013

4.  Reply to the letter to the editor regarding "Biologically effective dose for vestibular schwannomas: the truth and nothing but the truth".

Authors:  Jonathan Knisely; Marc Levivier; Constantin Tuleasca
Journal:  Neurosurg Rev       Date:  2022-06       Impact factor: 3.042

5.  Biologically effective dose correlates with linear tumour volume changes after upfront single-fraction stereotactic radiosurgery for vestibular schwannomas.

Authors:  Bleddyn Jones; John W Hopewell; Ian Paddick
Journal:  Neurosurg Rev       Date:  2022-03-15       Impact factor: 3.042

6.  Modelling the influence of treatment time on the biological effectiveness of single radiosurgery treatments: derivation of "protective" dose modification factors.

Authors:  Bleddyn Jones; John W Hopewell
Journal:  Br J Radiol       Date:  2018-08-21       Impact factor: 3.039

7.  The impact of unscheduled gaps and iso-centre sequencing on the biologically effective dose in Gamma Knife radiosurgery.

Authors:  Thomas Klinge; Marc Modat; Jamie R McClelland; Alexis Dimitriadis; Ian Paddick; John W Hopewell; Lee Walton; Jeremy Rowe; Neil Kitchen; Sébastien Ourselin
Journal:  J Radiosurg SBRT       Date:  2021

8.  Biologically effective dose correlates with linear tumor volume changes after upfront single-fraction stereotactic radiosurgery for vestibular schwannomas.

Authors:  Constantin Tuleasca; Mohamed Faouzi; Philippe Maeder; Raphael Maire; Jonathan Knisely; Marc Levivier
Journal:  Neurosurg Rev       Date:  2021-04-10       Impact factor: 3.042

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.